199 Annals of Clinical & Laboratory Science, vol. 39, no. 2, 2009 Abstracts of Presentations at the Association of Clinical Scientists’ 129th Meeting at Tampa, Florida, on 13 to 17 May 2009 [1] Claude P. Brown Memorial Lecture: Frontiers of ovarian cancer. Santo V. Nicosia, University of South Florida College of Medicine, Tampa, FL. Ovarian cancer represents the fifth most frequent malignancy in American women and the fourth leading cause of death in 40 to 59 year old women, with an estimated overall incidence of 21,650 cases and 15,520 deaths and a dismal diagnosis: death ratio of 1.4 in 2008. Eighty-five to 90% of ovarian malignancies are of so-called epithelial type although the nature of the epithelial cell of origin in still controversial. Approximately 90% of ovarian epithelial cancers (OEC) occur sporadically while 10% are genetically linked. Patients with OEC have a short median survival time after diagnosis and, even when the tumor is clinically localized, their 5-year relative survival rate is less than 40% regardless of therapy. Early stage OEC accounts for 30% of all malignancies and clearly represents an important target for screening as it is lethal in 25-30% of cases. This lecture will provide an overview of the current status and future vistas of basic and translational research in a disease defined as “insidious” and “silent killer” by both researchers and patient advocates. To establish the foundation of the topic, the lecture will begin by visiting key embryological, anatomical, and histological features of the human ovary. To review the topic in perspective and recognizing the educational value imparted by history, the lecture will then touch upon some of the key events in the discovery of the ovary and in the history of ovarian pathology. The main presentation will focus on OEC biology since meaningful progress in molecular biology must be based on a solid comprehension of cell, tissue, and organ biology. Translational aspects of OEC will be addressed by reviewing issues of current ovarian cancer management and detection, focusing on the most relevant characteristics of early, sporadic, and familial OEC and on the current status of cancer screening. The lecture will conclude by exploring the areas of future investigation, including current efforts at unraveling the natural history of OEC, which may shed light into the mechanisms responsible for the transformation of a tiny but important organ into a neoplastic mass not infrequently exceeding 5 to 10 inches in diameter at initial presentation. Upon completion of this presentation, participants should be able to discuss the pathobiology of ovarian epithelial cancer and describe current research on its detection and management. [2] Frontiers of research on Alzheimer’s disease. Huntington Potter, University of South Florida College of Medicine, Tampa, FL. Alzheimer’s disease is the most common neurodegenerative disease of the elderly, affecting 10% of individuals over age 65 and some 40% over age 85. Currently the available treatments merely slow the inevitable decline by perhaps a year or two. With the developing understanding of the genetics of Alzheimer’s disease and the role that environmental factors play in its development, it has become possible to create animal models of Alzheimer’s disease in the form of transgenic mice. These mice have been extensively studied in order to elucidate the pathogenic pathway that leads to Alzheimer’s disease and to develop more effective therapies. Several of these new therapies are able to completely prevent and in some case reverse Alzheimer’s pathology and cognitive decline in the mouse models and, as will be discussed, are now in or are being prepared for human clinical trials. It is highly likely that the results will show that no single approach will be best for all individuals and that a combination of drugs and lifestyle changes may be most efficacious. Upon completion of this presentation, participants should be able to describe the pathological features of Alzheimer’s disease, the cholinergic hypothesis of Alzheimer’s disease, and the cleavage of amyloid precursor protein into the A beta peptide. [3] Signal transduction pathways: A goldmine of anticancer drug targets. Said M. Sebti, University of South Florida College of Medicine, Tampa, FL It is believed that human cancer develops as a consequence of accumulations of genetic alterations that lead to activation of oncogenes and inactivation of tumor suppressor genes. These genetic alterations results in aberrant signal transduction pathways, which in turn, result in several hallmarks of cancer including: uncontrolled cell division, resistance to programmed cell death (apoptosis), and angiogenesis and metastasis. This lecture will describe innovative ways to discover and develop novel anticancer drugs based on interfering with the above mentioned aberrant signal transduction pathways. Specifically, the design of farnesyl and geranylgeranyl transferase inhibitors that target small GTPases such as Ras and Rho will be described. The effects of these novel anticancer drugs on signal transduction pathways in cancer cells will also be described. The speaker will discuss the discovery of other novel anti-cancer drugs based on interfering with pivotal signaling circuits in the cancer cell such as the PI3 kinase/Akt, the JAK/STAT3 and the BCLxL/Bax pathways. Examples will be given where laboratory discoveries from the bench were translated to hypothesis-driven clinical trials. Upon completion of this presentation, participants should be able to explain how aberrant signal transduction pathways contribute to malignant transformation of normal cells and how anti-cancer drugs can interfere with these pathways. 200 Annals of Clinical & Laboratory Science, vol. 39, no. 2, 2009 [4] Teratogenic causes for malformations. Enid GilbertBarness, Tampa General Hospital, Tampa, FL. Crucial morphogenetic processes ongoing during the blastogenesis period, which extends through the first 4 weeks of development, from fertilization until the end of the gastrulation stage (days 27 to 28 postconception), can be altered and result in several structural abnormalities, including patterns of multiple congenital anomaly (MCAs) resulting from developmental field defects. Severe damage may cause the death of the product of conception or, because of the pluripotential nature of the cells, the damage may be compensated allowing development to continue in a normal fashion. Most investigators believe that the all-or-none rule applies to the first 2 weeks of development. Because the fetus is less susceptible to morphologic alterations, because the development process of the majority of organs has been completed, the most common anomalies associated with teratogenic exposures during the fetal period are fetal growth restriction (intrauterine growth retardation) and mild errors of morphogenesis (abnormalities of phenogenesis), such as epicanthic folds, clinodactyly, and others. Thus, teratogenic exposures may result in a wide variety of effects that range from infertility, prenatal onset growth restriction, structural defects, or functional CNS abnormalities to miscarriage or fetal death. Upon completion of this presentation, participants should be able to delineate the FDA criteria for fetal risk, point out times during development when a specific substance may be teratogenic, and identify the developmental anomalies caused by certain drugs and chemicals. [5] Geriatric oncology: Integrating biologic variability into clinical research. Martine Extermann, Moffitt Cancer Center, University of South Florida, Tampa, FL. Personalized Cancer Care are buzzwords in oncology. Large efforts are poured into improving the targeting of cancer treatments by analyzing the molecular biology of the heterogeneous cancers that most solid tumors are. As most cancers occur beyond the age of 65, geriatric oncology is here to address the other component of Personalized Cancer Care: patient variability. Traditionally, clinical trials have sought to minimize patient variability in order to detect more sensitively treatment effects. This has resulted in underrepresentation of older patients in clinical trials. Furthermore, 60% of American retirees have at least one geriatric syndrome, and 90% have at least one comorbidity. Therefore variability is inescapable for an increasing proportion of patients in cancer trials. ECOG performance status is an insensitive adjustment factor in the elderly. Comorbidity is rarely recorded, yet its prognostic impact is as high as performance status. Furthermore, comorbidities can influence the behavior of the cancer itself, such as diabetes increasing the risk of relapse from colon cancer. The effect size is large enough to confound the impact of chemotherapy. As comorbidity is a complex concept, it would be desirable to identify biological markers to assess a patient’s functional reserve and level of fitness. Markers such as IL-6, D-dimers, albumin, and hemoglobin, are altered by aging and frailty. Comorbidities can alter levels of molecules such as VEGF and IGF-1. In an age of increasing use of targeted therapies, there is need for integrating better analyses of the patient side of the equation, if we want clinical trials to have optimal relevance for the majority of cancer patients. Upon completion of this presentation, participants should be able to recognize potential confounders that are not addressed by traditional oncology trial designs and list key biological markers that are relevant to aging and cancer. [6] Implementation of advanced molecular diagnostics at the James A. Haley Veterans Hospital. Stephen Mastorides, James A. Haley Veterans Affairs Medical Center, Tampa, FL The Pathology and Laboratory Medicine Service at the James A. Haley VAMC is the busiest and most complex laboratory in the VA Healthcare system, performing over twenty five thousand tests daily. The Molecular Diagnostics Section is part of a medical network of inpatient and outpatient facilities, providing molecular testing services for numerous VA medical centers in Florida. The laboratory performs over two thousand nucleic acid extractions per month and offers molecular infectious disease testing as well as pharmacogenomic testing. Our infectious disease menu includes PCRbased qualitative testing for hepatitis B, Chlamydia trachomatis and Neisseria gonorrhea, quantitative testing for hepatitis C and HIV, as well as hepatitis C and HIV genotyping. We routinely offeri to our clinicians cytochrome P450 2C9 and VKORC1 genotyping as recommended by the FDA for warfarin (coumadin) patients. The coumadin clinic serves 1874 patients with a total of 15382 visits annually. Individuals carrying variants in the CYP2C9 and VKORC1 genes are susceptible to reduced warfarin clearance leading to serious adverse effects, including life-threatening hemorrhage. This testing helps clinicians to optimize warfarin therapy while reducing serious side-effects. Upon completion of this presentation, participants should be able to explain pharmacogenomics testing modalities and their impact on patient care and cite examples of pharmacogenomics testing. [7] Atypical teratoid/rhabdoid tumor: Morphoproteomics defines its biology and exposes therapeutic targets. Robert E. Brown, Janet M. Bruner, and Johannes Wolff, UTHSC– Medical School at Houston and University of Texas-MD Anderson Cancer Center, Houston, TX. The atypical teratoid/rhabdoid tumor (AT/RT) is a highly aggressive central nervous system tumor that occurs in infants and young children. It is generally fatal with a mean postoperative survival of only 11 mo. AT/RT is associated with inactivation (deletion or mutation) of the hSNF5/INI1/ SMARCB1/BAF47, tumor suppressor gene resulting in upregulation of the cyclin D1 gene . The purpose of this study was to do morphoproteomic analysis on a case of AT/RT to define its biology and expose therapeutic targets. Immunohistochemical probes were applied to detect protein analytes related to the following: signal transduction pathways and their state of activation; cell cycle promoters and inhibitors; antiapoptotic/tumorigenic/angiogenic/chemoradioresistant factors; and tumoral stem cell markers. Results: correlative absence of INI1 protein with upregulation of cyclin D1;brisk G1 to S phase cell cycle progression associated with high Skp2 Abstracts, 2009 Annual Meeting of the Association of Clinical Scientists 201 expression in the nuclei, reduced cell cycle inhibitor expression (i.e., low p27Kip1 and p16INK4a nuclear proteins) and with a high mitotic index (20 mitotic figures/10 h.p.f ’s); constitutive activation of the Akt/mTOR/extracellular signal-regulated kinase (ERK)/beta-catenin and NF-kappaB pathways, all of which contribute to cyclin D1 expression; correlative expression of protein analytes associated with the transcriptional activation of their corresponding genes by p-NFkappaBp65 (i.e., VEGF-A, Bcl-2, GST-pi, and P-glycoprotein), the latter of which contribute to chemoradioresistance; and tumoral stem cell/endothelial precursor markers (ie, CD133, nestin, CD34 and CD44). These data show genomic and morphoproteomic correlates associated with upregulation of cyclin D1 and cell cycle progression in ATRT but also opportunities for therapeutic interventions targeting the cell cycle, the differentiation of the tumoral stem cells and the use of antiangiogenic agents to enhance tumoral necrosis. Upon completion of this presentation, participants should be able to discuss genomic and proteomic aspects of atypical teratoid/rhabdoid tumors and understand the application of morphoproteomics in exposing therapeutic targets in an individual patient’s tumor. [8] Overexpression of cancer stem cell markers in fibrolamellar hepatocellular carcinoma. Maryam J. Zenali, Dongfeng Tan, Robert E. Brown, and Wei Li., The University of Texas-Health Science Center at Houston, and The University of Texas-MD Anderson Cancer Center, Houston, TX. Fibrolamellar hepatocellular carcinoma (FL-HCC) remains a highly aggressive neoplasm due to high resistance to chemotherapy and radiation therapy. Cancer stem cells (CSCs) have been recognized responsible for the formation and growth of cancer tissue and are naturally resistant to chemotherapy and radiation therapy. Although involvement of CSCs in tumorigenesis and progression has been studied in many malignant tumors, the existence and role of CSCs in FL-HCC has not been explored. Formalin-fixed paraffinembedded tissue sections of 8 FL-HCC and 6 normal liver were selected. Mouse anti-human antibodies directed against CSCs markers (CD133 and CD44) were used. Expression levels of CD133 and CD44 were evaluated by immunohistochemistry using standard avidin-biotin techniques. Slides were scored using a semi-quantitative scoring scale based on intensity (weak +1, mild 2+, moderate 3+, strong 4+) and % immunoreactive cells (low = <25%, moderate 25 75%, and high >75%).The number of CD133 and CD44 positive cells and the intensity of immunostaining were significantly increased in FL-HCC compared with normal liver tissues (p < 0.001). Majority of FL-HCC tissue showed moderate (3+) to strong (4+) staining. In contrast, majority of normal liver parenchyma exhibited weak (1+) to mild (2+) staining. The immunostaining pattern was characterized by membranous as well as cytoplasmic stains.CD133 and CD44 are found and highly expressed in FL-HCC. These findings suggest that CSCs may play a potential role in FL-HCC formation. Our data could provide new insight into the FL-HCC tumorigenesis and bear better therapeutic implications. Additional studies are needed to characterize the role of CSCs in FL-HCC initiation and progression. Upon completion of this presentation, participants should be able to define the activation and possible role of stem cell marker upregulation in fibrolamellar hepatocellular caricnoma. [9] Morphoproteomics defines the NF-kappaB pathway in fibrolamellar hepatocellular carcinoma. Wei Li, Maryam J Zenali, Dongfeng Tan and Robert E Brown. The University of Texas Health Science Center-Medical School at Houston and The University of Texas-M.D. Anderson Cancer Center, Houston, TX. Fibrolamellar hepatocellular carcinoma (FL-HCC) is an aggressive neoplasm with high recurrence after surgical resection and with chemoradioresistance. The activation of the NF-KB pathway has been recognized for involvement in cellular proliferation and anti-apoptosis, and its constitutive activation is related to progression of various malignant neoplasms. Studies have demonstrated that NF-KB activation is an important mechanism for chemotherapy resistance, and that inhibition of NF-KB significantly enhances tumor cell response to chemotherapeutic agents. The purpose of this study was to determine whether the NF-KB pathway is constitutively activated and overexpressed in FL-HCC. Archival, paraffin-embedded tissue sections of 8 FL-HCC and 6 normal livers were selected. Phosphospecific antibody directed against NF-KBp65 (Ser 536) was used in an immunohistochemical assay. Expression levels of p-NFKBp65 (Ser 536) were scored by bright-field microscopy in tumor cells and non-neoplastic hepatocytes. These were categorized into 4 grades: 0 (background), 1+ (weak), 2+ (moderate), or 3+ (strong), based on intensity of intranuclear staining. The expression of p-NF-KBp65 was further assessed using 2 scales: high expression (2+ or 3+) and low expression (0 or 1+).High expression of NF- KBp65 was found in 88 % (7/8) of FL-HCC tissue. In contrast, only 17 % (1/6) of normal liver parenchyma showed high expression for NFKBp65 (p < 0.01). Increased expression of p-NF-KBp65 (Ser 536) in FL-HCC tissue suggests that constitutive activation and overexpression of this pathway may play a role in the biology of FL-HCC. This finding may have significant implications in the development and application of targeted therapy. Upon completion of this presentation, the participants should be able to explain the morphoproteomic assessment of the constitutive activation and overexpression of the NF-KB pathway in fibrolamellar hepatocellular carcinoma. [10] What we forgot to teach in medical school and why it matters. Stephen K. Klasko, University of South Florida College of Medicine, Tampa, FL. The future of academic health care is up for grabs. The very selection and educational biases that serve physicians and scientists well in their clinical and research role may be hindering our efforts to be leading change in quality, service and technology. Strategies to overcome these gaps in our faculty, resident, and student knowledge base and steps toward an optimistic future in health care will be outlined 202 Annals of Clinical & Laboratory Science, vol. 39, no. 2, 2009 and discussed, with the following objectives: (a) to understand the educational and selection mechanisms that have created biases which limit physicians and physician leaders from being successful in a changing healthcare environment; (b) to realize the power of creative thought in assisting health care leaders as they confront an ever changing environment; (c ) to understand how quality improvement/error reduction can be leveraged in negotiations and how changes in other service sectors will affect health care; (d) to recognize the revolution occurring in ambulatory health care delivery and how each physician will either be a leader or follower in that reform; and (e) to understand the current barriers to significant quality improvement impeding our movement to an optimistic health care future Upon completion of this presentation, participants should be motivated to initiate changes in the quality, service, and technology of academic health care. [11] Dysfunctional regulation of extracellular matrix assembly: Transgenic mice as a model of classic EhlersDanlos syndrome. David E. Birk, University of South Florida College of Medicine, Tampa, FL. The purpose of this work was to elucidate the mechanism(s) whereby alterations in type V collagen result in dysfunctional connective tissue biogenesis associated with the classic form of Ehlers-Danlos syndrome (EDS). EDS is associated with mutations in type V collagen genes. Type V collagen is a fibril-forming collagen that co-assembles with type I collagen regulating connective tissue structure and function. A mouse model with a targeted mutation in Col5a1 was analyzed. Null animals fail to assemble collagen fibrils and die during organogenesis. Heterozygous animals display features characteristic of the classic EDS phenotype. These mice are haploinsufficient with a 50% reduction in Col5a1 mRNA and type V collagen levels. The aortas from Col5a1+/mice have decreased stiffness and tensile strength. The skin was hyperextensible, demonstrating decreased tensile strength in wounded and unwounded skin. Col5a1+/- mice demonstrate defective collagen fibril formation. Dermal structure is disorganized and fibril number is reduced. Heterozygous animals assemble two subpopulations of fibrils. One is relatively normal with cylindrical profiles and a second consists of structurally aberrant fibrils with irregular shapes. As the dermis matures the subpopulations intermix. The data indicate that a reduction in type V collagen reduces the initiation of fibril assembly. Therefore, in dermis where type V collagen content is limiting, fewer fibrils are assembled into two subpopulations: one containing relatively normal fibrils with type I/V interactions; and a second with an unregulated sequestration of type I collagen. The presence of the aberrant fibril subpopulation disrupts fibril maturation. Therefore, abnormal fibril nucleation, dysfunctional fibril growth, and potential disruption of cell directed fibril organization lead to the disruption of function associated with the EDS phenotype. Upon completion of this presentation, participants should be able to define the structural alterations associated with type V collagen mutations and the functional consequences; characterize the relationship between structural abnormalities and clinical phenotype in classic EDS; identify tissue-specific differences in structural/function dysfunction as a result of the disease phenotype; and define the regulatory mechanism of type I/V collagen interaction in extracellular matrix assembly and function. [12] A good ending makes a good beginning: The telomere theory of reproductive aging. David L. Keefe, University of South Florida College of Medicine, Tampa, FL. Infertility, miscarriage, and aneuploid offspring increase with age in women, and meiotic dysfunction underlies reproductive aging. How aging disrupts meiotic function in women remains unclear, but as women increasingly delay attempts at childbearing, solving this problem becomes an urgent priority. Telomeres, which mediate aging in mitotic cells, also may mediate aging during meiosis. Telomeres shorten both during DNA replication and from the response to oxidative DNA damage. Oocytes do not divide in adult mammals, but their precursors did replicate during fetal oogenesis, and eggs ovulated from older females traversed more mitotic cell cycles before entering meiosis during fetal oogenesis than eggs ovulated from younger females. Telomeres also would be expected to shorten from the DNA repair response to oxidative damage, because the interval between fetal oogenesis and ovulation is exceptionally prolonged in women. We have tested the hypothesis that telomere shortening disrupts meiosis by experimentally shortening telomeres in mice, which normally do not exhibit age-related meiotic dysfunction. Interestingly, mouse telomeres are much longer than human telomeres, but genetic or pharmacologic shortening of mouse telomeres recapitulates in mice the human reproductive aging phenotype as the mouse telomeres reach the length of telomeres from older women. These observations led us to propose a telomere theory of reproductive aging. Finally, if telomeres shorten with aging, how do they reset across generations? Telomerase could not play a significant role in telomere elongation during early development, because this enzyme is not active until the blastocyst stage, well after the stage when telomere elongation takes place. Rather, telomeres lengthen during the early cell cycles of development by a novel mechanism involving recombination and sister chromatid exchange. Upon completion of this presentation, participants should be able to discuss the effects of meiotic non-disjunction on female reproductive aging, explain the role of telomeres in meiosis, and summarize the data that support the telomere theory of reproductive aging. [13] Congenital hepatorenal fibrocystic syndromes: Advances in molecular pathology and genetics. Consolato Sergi, University of Alberta Hospital, Edmonton, Canada. The hepatorenal fibrocystic (HRFC) syndromes are a heterogeneous group of severe monogenic conditions that may be detected before birth. Commonly, HRFC syndromes present in the neonatal and pediatric age, with consistent developmental abnormalities mostly involving the liver and kidney. HRFC disease is characterised by changes in the parenchymal tissues of the liver, kidney, and sometimes pancreas or other organs. They include the proliferation and Abstracts, 2009 Annual Meeting of the Association of Clinical Scientists 203 dilatation of epithelial ducts, and proliferative changes in the extracellular matrix of stromal connective tissue. One of the manifestations that has received intensive study is related to the ductal plate malformation of the liver and comprises proliferation and dilation of peripherally-located intrahepatic biliary structures, with a variable degree of fibrosis and cyst formation. The clinical features and differential diagnoses of this group of syndromes, including autosomal recessive polycystic kidney disease (ARPKD), juvenile nephronophthisis (NPHP), Meckel-Gruber syndrome (MKS), Bardet-Biedl syndrome (BBS), and Jeune asphyxiating thoracic dystrophy (JATD) are reviewed. Extrahepatic manifestations include mostly bone and central nervous system abnormalities, dysmorphic features, and developmental delay. The longest open reading frame of PKHD1 (polycystic kidney and hepatic disease 1), the autosomal recessive polycystic kidney disease (ARPKD) gene, encodes a singlepass, integral membrane protein named polyductin or fibrocystin. A fusion protein comprising its intracellular Cterminus, FP2, was previously used to raise a polyclonal antiserum shown to detect polyductin in several human tissues, including liver. The expression of polyductin in several HRFC syndromes and liver diseases is reported. Upon completion of this presentation, participants should be able to describe the molecular pathology and genetics of the common hepato-renal fibrocystic diseases and discuss the expression of polyductin in these diseases. [14] Promises and challenges in cancer immunotherapy. Dimitry I. Gabrilovich, H. L. Moffitt Cancer Center and University of South Florida College of Medicine, Tampa, FL. Cancer immunotherapy is a treatment strategy utilizing a unique set of antigens able to discriminate between normal and neoplastic cells. There are numerous examples of successful generation of immune responses against tumorassociated antigens. However, clinical results so far have been discouraging. One of the main limitations of cancer immunotherapy is the existence of numerous mechanisms that allow tumor cells to escape immune system control. Novel strategies to counter the effect of these mechanisms have been developed and some of them have demonstrated promise in clinical trials. Upon completion of this presentation, participants should be able to summarize the successes and failures of current immunotherapy regimens and evaluate the different mechanisms of tumor induced immune suppression. [15] Overview on the evolution of the innate and adaptive immune systems culminating in adoptive immune lymphocyte therapy. Joseph G. Sinkovics, St. Joseph Hospital’s Cancer Institute, H. L. Moffitt Cancer Center, and University of South Florida College of Medicine, Tampa, FL Virally-mediated fusion of ancient archaebacterial and prokaryotic protoplasts might have created the first eukaryotes. Extant fusogenic phages may re-induce these primordial events. The relationship of the first eukaryotes with viruses evolved under mutual genetic pressures resulting in siRNA defense reactions, or early apoptotic deaths, of the cell, occurring before the maturation of the viral progeny. In response, viral genes encoding anti-apoptotic proteins evolved. After the first multicellular organisms acquired the machinery of interferon generation, viruses developed gene product proteins to neutralize interferons. The first multicellular hosts recognized pathogens by Toll-like receptors and chemokines and by the variable lymphocyte receptors consisting of leucine-rich repeats. They defended themselves throughout millennia by mobilization of phagocytes and by secretion of bactericidal substances (defensins). Superimposed on the faculties of the innate immune system (phagocytes, dendritic cells, NK cells), the adaptive immune system emerged with specific immunoglobulin-producing B, and cytokine-producing cytolytic immune T lymphocytes. Horizontal acquisition of retrotransposons might have encoded the entire adaptive immune system. Placentation compromised the adaptive immune system, forcing it to accept the semiallogeneic fetus. In mammalian hosts the placenta mobilizes Th2-type immune reactions in the mother; so do a number of pathogens and malignantly transformed cells in their hosts. Pathogens under genetic pressure learned how to survive in the infected host. Malignant cells often immunosuppress their hosts and are able to induce subverted host reactions (chemokines, cytokines) for the promotion of their own growth. Yet monoclonal antibody and adoptive immune lymphocyte therapy could eliminate pathogens and malignant cell populations and secure complete remissions, maybe cures, of the afflicted hosts. Upon completion of this presentation, participants should be able to review the evolution of the immune systems and explain adoptive immune lymphocyte therapy. [16] Myeloproliferative neoplasms: Role of JAK2 mutations. John Lazarchick, Medical University of South Carolina, Charleston, SC 29425 Myeloproliferative neoplasms are clonal disorders of hematopoietic progenitor cells and include chronic myelogenous leukemia (CML), polycythemia vera (P Vera), essential thrombocythemia (ET), and primary myelofibrosis (PMF), in addition to chronic eosinphilic leukemia and systemic mastocytosis. Each of these is characterized by distinct but not exclusive clinicopathologic features. Mutant alleles resulting in constitutive activation of tyrosine kinase activity are the hallmark of CML but had not been noted in P Vera, ET, or PMF until the recent identification of mutations that activate JAK2 signaling in patients with these neoplasms. JAK2 is a member of the Janus kinase family of intracellular non-receptor tyrosine kinases that transduce cytokinemediated signaling via the JAK-STAT pathway. The pathophysiologic role of JAK2V617 mutation in these disorders and possible treatment with JAK2 inhibitors will be discussed. Upon completion of this presentation, participants should be able to tabulate the clinical-pathologic spectrum of myeloproliferative neoplasms by the WHO classification, discuss the role of mutation of JAK2 kinase (JAKV617F) in development of polycythemia vera, essential thrombocythemia, and primary myelofibrosis, and speculate about the potential role of JAK2 inhibitors in their therapy. 204 Annals of Clinical & Laboratory Science, vol. 39, no. 2, 2009 {17] Morphoproteomics of multiple signaling pathways in anaplastic thyroid carcinoma. Jing Liu and Robert E. Brown, University of Texas Health Science Center at Houston Medical School, Houston, TX. Anaplastic thyroid carcinoma (ATC) is a highly aggressive tumor resistant to radiation and chemotherapy. Individualized targeted therapies may be an effective strategy against ATC. However, signaling pathways involved in its tumorigenesis are not quite understood. Studies reported in the literature are limited to scattered genes and their products. We studied multiple signaling pathways in 2 patients with ATC using archival paraffin-embedded tissue. For comparison, 30 normal thyroid tissue sections from 30 patients were studied. Immunohistochemical stains were performed for detection of following antigens: p-p38 MAPK, p-ERK1/2 (Thr202/Tyr 204), p-Akt (Ser 473), p-mTOR (Ser 2448), pp70S6K (Thr 389), p-NF-κBp65 (Ser536), PLD1, IL-8, GSTpi, p27, Skp2, Ki-67, and cyclin D1. Both staining intensity (0 to 3+) and extensiveness (0 to 100%) were evaluated. Positivities for p27, Skp2, Ki-67 and cyclin D1 were calculated by an automatic imaging system, as measured by percentages of tumor cell nuclear immunostaining. Mitotic index (MI) was calculated as the number of mitoses per 10 high power fields (10HPF). Moderate or strong (2+ or 3+) and extensive (≥50%) expressions of p-NF-κBp65, p-mTOR, PLD1, pERK1/2, p-Akt, p-p38 MAPK, p-p70S6K, IL-8 and GST-pi were present in both ATCs. Nuclear translocation of p-NFκBp65, p-mTOR and p-ERK1/2 was noted. There were increases in Ki-67 (32%), Skp2 (51%), cyclin D1 (36%) and MI (8/10HPF) and a decrease in p27 (0%) in ATCs in comparison with normal controls. The results indicate constitutive activation of multiple signaling pathways including MAP kinase, mTOR, and PLD (phospholipase D1)/ p70S6K pathways in ATCs, which converge on the NFκB pathway. The activations of such pathways promote progression from G1 to S and mitotic phases as evidenced by increased Ki-67, Skp2, cyclin D1 and mitotic indices in ATC’s. This is a pilot study and the results warrant future studies on a large series of cases in order to provide molecular basis of signal transduction pathways for clinical therapy. Upon completion of this presentation, participants should be able to list some of the signaling transduction pathways that may be upregulated in anaplastic thyroid carcinoma. [18] Modulation of survival and death pathways by sanguinarine in neuroblastoma cells. Priya Weerasinghe, Tushar Acharya, and Robert E. Brown. University of Texas Medical School at Houston, Houston, TX. Neuroblastoma is predominantly a disease in children. It is the most common cancer among patients less than one year of age, accounting for 15% of all pediatric cancer fatalities. Natural products have greatly influenced the development of antitumor agents. Sanguinarine, a naturally occurring benzophananthridine alkaloid extracted from plants of the papaveraceae family, has been well studied in the laboratory despite having no documented use as a conventional chemotherapeutic agent in the clinic. We set out to investigate the effects of sanguinarine on neuroblastoma cells. Cells treated with 0.375 µg/ml of sanguinarine for 24 hr revealed classic morphological apoptosis when examined using light and electron microscopy. Western blotting of sanguinarinetreated cells showed a dose-dependent decrease in p-AKT (Ser 473) and p-p70S6K (Thr 389), while showing proteolytic activation of caspase-3. This study provides the first evidence of sanguinarine’s being effective against neuroblastoma cells via inhibition of pathways involved in survival (ie, AKT and p70 S6K). Molecular characterization of sanguinarine-treated cells could reveal important molecular targets for effective adjuvant therapeutics for neuroblastoma patients. Upon completion of this presentation, participants should be able to explain how specific signaling molecules might be used as drug targets to design effective therapies to combat neuroblastoma. [19] New trends in liquid chromatography–tandem mass spectrometry. Joseph P. Laurino, The University of Tampa, Tampa, FL. Liquid chromatography–tandem mass spectrometry (LC/MSMS) is an emerging technology in the clinical laboratory. LC/MSMS has been used to measure a broad range of compounds, such as androgens (testosterone and dihydroxytestosterone), proteins (thyroglobulin), 25-hydroxy vitamin D, low molecular weight organic acids (methylmalonic acid), and both therapeutic and illegal drugs. Recent advances in instrument automation and reliability have facilitated the entry of this analytical technique into the clinical laboratory. This presentation will summarize the major classes of mass analyzers and the frequently used modes of ionization, with special emphasis given to the benefits and limitations associated with each process. An overview of the common analytes measured by LC/MSMS in the clinical laboratory will be presented, and the implementation of LC/MSMS methods in the clinical laboratory will be outlined. Upon completion of this presentation, participants should be able to describe the various mass analyzers, the various ionization techniques, and the advantages and limitations of each method for use in clinical laboratories. [20] A chemistry analyzer is much the same as any other chemistry analyzer, or is it? Clive R. Hamlin, Case Western Reserve School of Medicine, Cleveland, OH. Leonard Skeggs and his colleagues, through ingenuity and serendipity, created the first automated clinical chemistry analyzer. This continuous-flow technique was commercialized by a single company, but is no longer in common use. Another unique slide-based technique was conceived and commercialized by another single company, and is still commonly used. Tests performed in a spectrophotometer’s cuvette predate both the former techniques, and many companies in several countries attempted to automate this procedure. Improvements in design have improved the cuvette-based technique such that it now dominates clinical chemistry worldwide. A few companies in Japan manufacture most of the instruments, all using components from single manufacturers. Despite this, these companies have unique histories and the companies’ expertise is incorporated into Abstracts, 2009 Annual Meeting of the Association of Clinical Scientists each company’s product. These differences can become important when choosing one analyzer versus another. Upon completion of this presentation, participants should be able to choose an appropriate chemistry analyzer for their clinical laboratory. [21] Determination of urinary myo-inositol on an automated chemistry analyzer. Zak K. Shihabi, Krista J. Garrison, and Barry I. Freedman, Wake Forest University School of Medicine, Winston-Salem, NC. The objective of this work is to adapt an enzymatic method for myo-inositol (MI) determination on the Beckman DX 800 chemistry analyzer. MI is synthesized from glucose through isomerization and it is also derived from the diet. It is mainly incorporated into cell membranes. MI is decreased in the nerves of patients with diabetic neuropathy and it is also decreased in the cerebrospinal fluid of patients with affective disorders. MI has been sugggessted as a screening method for impaired glucose tolerance. Existing methods for analyzing MI are based on chromatographic methods that are difficult to use routinely. Herein, we describe the adaptation of an enzymatic method for urinary MI (Lucica MI, Asahi Kasei Pharma Corporation, Chiyoda-ku, Tokyo, Japan) on the Beckman DXC 800. This method is based on conversion of MI to myo-inosose by the enzyme MI dehydrogenase, with formation of thio-NADH from thio-NAD. After urine samples were mixed with the reagents on the instrument, two readings were recorded at 4 and 10 min at 410 / 670 nm. The test was linear between 0 and 775 µmol/L of MI (r = 0.995). The mean ± SD of 10 samples of urine from normal patients was 22 ± 15 µmol/g creatinine (n = 12), compared to 507 ± 730 (n=10) from patients with nephropathy, and 751 ± 796 (n= 12) µmol/g creatinine in diabetic non-nephropathy patients. MI increased 1.4 fold after 2 hr of ingestion of 75 g of glucose in normal individuals (n = 7) vs 13.9 fold in diabetic subjects (n = 7). Common interfering substances, such as glucose (20 g/L), ascorbate (10 g/L), uric acid (1 g/L), and sorbitol (1 g/L) did not interfere with this test. The cerebrospinal fluid (CSF) MI can be assayed directly by this method. The mean ± standard deviation for CSF samples was 111 ± 26 µmol/L (n = 20). In conclusion, the new enzymatic method for determination of urine MI on the Beckman instrument is fully automated, specific, and easy to perform, compared to chromatographic methods Upon completion of this presentation, participants should be able to discuss the enzymatic analysis of myoinositol and its clinical applications in diabetic patients. [22] Using an automated camera system to rapidly inspect for mislabeled specimens. Charles D. Hawker, ARUP Laboratories and University of Utah, Salt Lake City, UT. Clinical laboratory automation vendors are now incorporating systems to inspect specimens for correct specimen type, serum volumes above packed red cells, and interferences such as fibrin, hemolysis, icterus, and lipemia. These systems are generally known in industry as machine vision systems. Depending on design, some are capable of inspecting specimens through the sides of tubes covered with labels. They usually require extensive computer software for 205 analysis and data interpretation. As cost reduction pressures on laboratories increase and the supply of medical technologists continues to diminish, automated inspection will become increasingly important. One very critical area for laboratory inspection is mislabeled specimens. Most laboratories are aware that they have mislabeled specimens, and require employees to carefully inspect all specimens. A recent CAP Q-Probe study (Arch Path Lab Med, 2008;130:1662-1668) found an average incidence in 147 reporting laboratories of 1 mislabeled specimen per 1000 specimens processed. We have developed an automated system for camera inspection of the patient’s name on the client’s label to determine if a specimen has been mislabeled. The system employs one camera to determine tube dimensions and four equidistant cameras to create a two-dimensional image of the entire tube circumference. It uses optical character verification (OCV) software to find a character string within the total image, but outside the zone of our laboratory label, that matches our bar coded computer record of patient name. Only 3 sec are needed for image acquisition and assembly and for OCV analysis. After a year of validation (proof-of-principle), pass-fail messages from the inspection computer will direct routing on our automated track system of all “fail” tubes to human inspection stations. Upon completion of this presentation, participants should be able to design strategies to reduce the incidence of mislabeled samples in their clinical laboratories. [23] Minor metabolic products of opiate metabolism: potential for misinterpretation of urine drug testing results. Roger L. Bertholf and Gary M. Reisfield. University of Florida Health Science Center, Jacksonville, FL. Urine drug testing is a prominent feature in the current practice of chronic pain management. In patients prescribed opioids, evidence indicates that the potential for drug abuse is high. Additionally, the street value of prescription opioids raises concerns about their diversion. Therefore, physicians treating patients with chronic opioid therapy often test their patients’ urine to verify adherence with the prescribed regimen, as well as to detect the use of illicit or unauthorized licit drugs. Unexpected results on the urine drug screen may lead to termination of opioid privileges or dismissal from the medical practice. Concerns have been raised regarding the ability of physicians to correctly interpret the results of urine drug screens; in this context, knowledge of the anticipated metabolic products of commonly prescribed opioids is essential for correct interpretation. The metabolic conversions of codeine to morphine, and of heroin to 6-acetylmorphine and morphine, have been widely reported. Metabolism of hydrocodone to hydromorphone also has been described. However, there have been recent reports of the detection of hydromorphone in the urine of patients purported to be only taking morphine, and hydrocodone in the urine of patients only taking codeine. These purported metabolic conversions, if validated, would be important because hydromorphone and hydrocodone are themselves prescription opioids, and historically, their presence in urine has been taken as evidence of use of those drugs, rather than as expected metabolites of morphine and codeine, respectively. We present a case in 206 Annals of Clinical & Laboratory Science, vol. 39, no. 2, 2009 which hydromorphone was detected in the urine of a woman on high dose morphine therapy, who had been sequestered in an inpatient hospice unit for the 12 weeks prior to her death, effectively eliminating the possibility of exposure to nonprescribed opioids. Upon completion of this presentation, participants should be able to describe the common pathways of opiate metabolism, list two minor metabolites of morphine and codeine, and explain how opiate metabolism influences the interpretation of urine drug testing results. [24] Estimated average glucose: Why? Frederick L. Kiechle, Memorial Regional Hospital, Hollywood, FL The Diabetes Control and Complications Trial (DCCT) and United Kingdom Prospective Diabetes Study clearly demonstrate the relationship between the risk for diabetes complications and Hb A1C . These two studies set the stage for establishment of specific diabetes treatment goals using Hb A1C as an index of mean glycemia. Recently, a linear relationship between the estimated average glucose and Hb A1C has been established: eAG (mg/dL) = 28.7 x Hb A1C – 46.7 (Nathan DM, et al. Diabetes Care 2008;31:1-6.) To evaluate the clinical value of this calculation, the literature and physicians were queried. Approximately 50% of physicians interviewed used Hb A1C for screening and diagnosis of diabetes mellitus. Most Hb A1C assays have a CV <2%. The estimated average glucose derived from Hb A1C in the DCCT was greater than the 2008 linear regression or A1C -derived average glucose (ADAG) formula (3.1%, 97 mg/dl to 15.2%, 269 mg/dl). This difference is attributable to improvements in Hb A1C methods from 1993 to 2008. The ADAG formula was derived from glucose meter and interstitial fluid glucose measurements. The latter were scaled up 5% since interstitial fluid glucose is 5% lower than simultaneously collected capillary glucose values. The primary incentive for providing the eAG with the H A1C on one report is to aid in patient education regarding the direct relationship between serum glucose and glycated hemoglobin. In conclusion, estimated average glucose (ADAG) calculated from HbA1C levels provides a value a diabetic patient can relate to his/her daily glucose monitoring practice. Upon completion of this presentation, participants should be able to estimate the average daily blood glucose levels of their patients, based on measurements of Hb A1C . [25] Improving detection in capillary electrophoresis: Example of serum mycophenolic acid. Zak K. Shihabi, Wake Forest University and Baptist Medical Center, WinstonSalem, NC. The objective of this study is to improve the detection limits in capillary electrophoresis (CE) using the analysis of mycophenolic acid as an example. One of the main practical shortcomings of CE in routine clinical analysis is the poor light absorbency detection limits, which are about 30-60 times less sensitive when compared to HPLC. Several strategies have been described to remedy this problem but none alone is sufficient to bring along the detection limits of the CE to those of HPLC. In order to overcome this problem, three simple and general strategies were combined to increase the amount of the sample injected and to increase the light path: (a) a long capillary to hold extra sample, (b) stacking (acetonitrile), which concentrates the sample based on transient pseudo-isotachophoresis and (c ) using at the same time a wide capillary for better signal to noise ratio. The combination of these strategies yielded sensitivity comparable or better than that of HPLC with good peak resolution and better theoretical plate number. The analysis of mycophenolic acid, a common immunosuppressant drug, in serum was used as an example to illustrate this enhanced detection and its applicability to therapeutic drug monitoring. Acetonitrile was used to remove serum proteins and induce sample concentration on the capillary, followed by direct injection filling 5-21% of the capillary volume with sample and separation in a borate buffer. The minimum detection level for mycophenolic was 95 µg/L for CE vs 125 µg/L for HPLC. Also, in this case, the apparent theoretical plate number for MPA peak is much better by the CE compared to HPLC, 53,265 vs. 4,620, respectively. In conclusion, the overall CE method for mycophenolic acid compared well to an assay by HPLC as far as sample preparation, correlation coefficient, and especially sensitivity of detection. Upon completion of this presentation, participants should be able to list three ways to enhance the detection limits of capillary electrophoretic analysis. [26] Liquid chromatography-tandem mass spectrometry workshop. Scott Allen, University of Tampa, Tampa, FL. Participants will prepare a therapeutic drug sample for analysis, tune the mass spectrometer on the analyte of interest, and evaluate the mass spectral data obtained from the analysis. Optimization parameters, modes of ionization, sample concentration limitations, and carryover restrictions will be discussed and evaluated. Unknown compounds will be identified using a data base program containing representative mass spectra. Upon completion of this presentation, participants should be able to tune the mass analyzer on the compound of interest, optimize instrument parameters, interpret mass spectra and identify spectral matches in a library database. [27] Inductively coupled plasma–atomic emission spectroscopy workshop. Joseph P. Laurino, University of Tampa, Tampa, FL. Inductively coupled plasma–atomic emission spectrometry (ICP-AES) is a frequently used technique for elemental analysis. This method has several advantages over traditional flame atomic absorption spectrometry. Due to the high degree of stability associated with the plasma source, the ability to overcome depressive interference effects caused by the formation of stable compounds, the ability to excite several elements that are not excited in traditional chemical flames, and the increased sensitivity of detection, this technique is generally favored over flame photometry. Participants in this workshop will prepare representative standard curves and simultaneously analyze digested tissue samples for calcium, sodium, and zinc. Analysis of spectral curves, determination of potential interfering substances, and the use of internal standards will be demonsstrated. [29] Surgical pathology tutorial on cancers of the colon and breast. Domenico Coppola and Geza Acs, with case presentations by pathology residents and fellows (Evita Henderson-Jackson, Rahel Mathew, and Masoumeh Ghayouri), H. Lee Moffitt Cancer Center and University of South Florida College of Medicine, Tampa, FL. Interesting and challenging cases of colon and breast cancer will be presented by pathology residents and fellows for discussions of histologic findings, tumor classifications, prognoses, and therapeutic considerations by two expert surgical pathologists and by the participants. Upon completion of this presentation, participants should be able to hone their diagnostic skills in surgical pathology of the colon and breast. [30] Integration of histology and molecular biology in the therapeutic planning for colon cancer. Domenico Coppola, H. Lee Moffitt Cancer Center, Tampa, FL. [28] Workshop on instrumental advances in molecular diagnostics. Maura Pieretti, BayCare Health System, Clearwater, Florida Until approximately 20 years ago molecular technologies were almost exclusively found in research, academic, and specialized laboratories. DNA and RNA extractions were tedious and labor intensive procedures, fraught with inconsistencies and low level reproducibility. As molecular technologies become increasingly utilized in several clinical disciplines, we are witnessing automation and simplification of molecular tests. Automation is now available for nucleic acid extraction, amplification, and detection, as well as various sample handling steps. Examples of automated instruments that are currently utilized in clinical molecular laboratories will be presented during the workshop. An automated platform for the detection of Enterovirus (EV) in cerebrospinal fluid (CSF) will be demonstrated. This platform utilizes real time PCR and automates the extraction, amplification, and detection steps of the assay. The utilization of this technologically advanced, yet simple and rapid test within our health care system allows the rapid diagnosis of EV meningitis. Turn-around times improved dramatically after implementation of this rapid test at two of our Microbiology Departments; clinician and patient satisfaction have also significantly increased. Length of hospital stay for patients with suspected viral/bacterial meningitis was studied before and after implementation of this test and a reduction from an average stay of 4.2 days to 2.2 days was observed. Upon completion of this presentation, participants should be able to describe the trend from manual to automated technologies in clinical molecular diagnostics, list examples of automated instruments used in clinical molecular laboratories, and describe the automated detection of EV by real time PCR. Upon completion of this presentation, participants should be able to prepare a suitable standard curve for ICPAES analysis, detect potential interfering substances, describe the use of internal standards, and determine the concentrations of various elements in a tissue sample. Abstracts, 2009 Annual Meeting of the Association of Clinical Scientists 207 Recent studies have shown that a gamut of different molecular pathways may be responsible for colon cancer. Each of the molecular pathways relates to specific histopathological findings. Here we describe molecular alterations characteristic of the microsatellite instable pathway, and of the APC pathway. In addition, we review the use of important predictor markers of therapeutic response and survival. These markers, including among others, thymidylate synthase, ERCC1, topoisomerase 1, uridine diphosphate glucoronosyl-transferase (UGT1A1), and K-Ras, illustrate the attempt to provide targeted/personalized therapy. We also present recent developments in the identification of gene and protein signatures capable of predicting tumor response to therapy. Finally, we present an overview of the Total Cancer Care program, a Moffitt Cancer Center initiative furthering the vision for a personalized/tailored cancer care for each patient to maximize efficacy and minimize toxicity of therapy. Upon completion of this presentation, participants should be able to recognize the features of hyperplastic polyp and sessile serrated adenoma, list the components of the MSI and APC pathways, identify the targets for the most common chemotherapeutic agent used for the therapy of colon cancer, and discuss recent developments in gene and protein profiling for colon cancer. [31] Constitutively active erythropoietin receptors in the growth of human cancer. Geza Acs, H. Lee Moffitt Cancer Center, Tampa, FL Human recombinant erythropoietin (Epo) is widely used in the management of cancer and therapy related anemia in patients with malignant neoplasms. Although Epo is effective in correcting anemia and improving quality of life, recent clinical trials suggest that its use may be associated with earlier tumor recurrence/progression and decreased survival. Various human cancer cells were recently shown to express Epo receptor (EpoR) and in vitro studies suggested that Epo can stimulate signaling mechanisms and proliferation in some cancer cells. Other studies, however, found that exogenous Epo failed to stimulate tumor growth in in vivo tumor models. Given the lack of biologic response to Epo despite the presence of high levels of EpoR in some tumor cells, we tested the hypothesis that EpoR is constitutively active and contributes to tumor growth independent of Epo in such tumors. We found that despite expression of high levels of EpoR, exogenous Epo fails to stimulate EpoR-related signaling mechanisms, proliferation, or invasiveness in A2780 human ovarian carcinoma cells. We have down-regulated EpoR expression in A2780 cells using a short hairpin RNA (shRNA) expression plasmid, which resulted in markedly suppressed cell proliferation and invasiveness in vitro, and abrogation of tumor growth in vivo. Western blot analysis revealed decreased activation status of EpoR signaling pathway components in A2780/EpoR shRNA tumors compared to controls. In order to examine the potential mechanisms of constitutive EpoR signaling in breast and ovarian cancer cells, we measured the mRNA expression levels of the EpoR gene exons. We found that mRNA regions coding for the extracellular portion of EpoR were expressed at significantly lower levels compared to C-terminal regions, 208 Annals of Clinical & Laboratory Science, vol. 39, no. 2, 2009 suggesting the presence of altered EpoR mRNA species in these cancer cells. Increased ratio of C- vs N-terminal EpoR mRNA levels determined by qualitative RT PCR in breast cancer samples significantly correlated with lymphatic invasion and nodal metastasis. A SMART RACE PCR assay confirmed the presence of altered EpoR mRNA variants in breast and ovarian cancer cells. Our findings suggest that variant forms of EpoR may be constitutively active in some cancer cells and provide the first evidence for the potential role of an Epo independent EpoR mediated pathway in tumor growth. Upon completion of this presentation, participants should be able to describe our current understanding of the role of erythropoietin receptor in the biology of malignant neoplasm and the potential role of constitutively active altered erythropoietin receptor variants in the growth of tumors. [32] Granulomatous prostatitis secondary to M. tuberculosis complex. Frank M. Taylor, III, Salim Afridi, Bienvenido Yangco, and A. John Saranko, South Florida Baptist Hospital, Plant City, FL. We report a rare case of infectious granulomatous prostatitis that was diagnosed in a 69-yr-old African-American man. The patient presented with severe lower back pain and was found to have lytic lesions of the lumbar spine, an enlarged prostate gland, and elevated serum level of prostate-specific antigen. Despite our strong initial suspicion of prostate adenocarcinoma with metastases, tissue studies revealed granulomatous prostatitis and orchitis secondary to M. tuberculosis complex, as determined by PCR. Salient clinical and laboratory features are discussed. Upon completion of this presentation, participants should be able to distinguish the various subtypes of granulomatous prostatitis and related disorders. [33] Iron in neurodegeneration. Joseph C. Parker, Jr., University of Louisville School of Medicine, Louisville, KY. Iron distributed throughout the human body plays a major role in the production of free radicals. Too much dietary iron causes hemosiderosis; too little produces altered hematopoiesis with iron deficiency anemia, a major worldwide nutritional problem. Behavior and cognitive developmental delays with iron deficiency are related to abnormal neurotransmission, decreased myelin formation, and altered brain energy metabolism. Iron concentrations in the normal brain are most prevalent in the basal ganglia, substantia nigra, and deep cerebellar nuclei. Iron appears high in the brain at birth and decreases through the first year of life increasing with myelination and increased transferrin. With aging, iron increases in a random distribution in the brain. In hereditary and sporadic neurodegenerative disesases such as Hallervorden-Spatz syndrome (neurodegeneration with brain iron accumulation), Alzheimer’s disease, and Parkinson’s disease damage to neurons occurs with accumulated free radicals associated with the iron catalytic Fenton reaction (H2O2 + Fe2+ → Fe3+ + OH- + OH•) in mitochondria. Over-expression of iron uptake from transferrin receptors has been found with excessive iron deposition related to increased hydroxyl radicals (OH•), mitochondrial insufficiency, and apoptotic neurons. Altered brain iron metabolism in neurodegenerative diseases has multiple causes that include genetic and non-genetic factors related to altered iron uptake, release, storage, and metabolism. Iron induced free radicals seem to play a major role in many neurodegenerative disorders with oxidative stess being a central feature. Chelation (desferrioxamine) and antioxidant treatment (CoQ10) slow the neurodegenerative process while altering proteins involved with iron absorption and transport such as hepcidin may help. Upon completion of this presentation, participants should be able to identify the neurological disorders that are associated with disturbed iron metabolism and free radicals. [34] Papillary tumor of the pineal region: Two unique case studies. Kyle Rickard, John R. Parker, Stephanie Wagner, Todd Vitaz, and Joseph C. Parker, Jr., University of Louisville School of Medicine, Louisville, KY. Papillary tumor of the pineal region (PTPR) is a newly recognized distinct entity in the 2007 World Health Organization nomenclature; it is characterized by epithelialappearing areas with papillary features and more densely cellular areas that often display ependymal-like differentiation. Ultrastructurally, this rare neuroepithelial tumor possesses secretory and ependymal organelles that likely originate from the subcommisural organ. Forty described cases worldwide have been recognized, with ages ranging from 5 to 66 yr (mean age = 32 yr). Clinical presentation most often includes headache and obstructive hydrocephalus. The tumor, which is well circumscribed, may be cystic and grossly is usually considered a pineocytoma. Microscopic evaluation often demonstrates a lesion with atypical small and intermediate size epitheloid tumor cells with scattered eosinophilic cytoplasm found in sheets and perivascular clusters in a papillary pattern. Perivascular, neuroblastic, and true rosettes may be identified. Distinctive immunohistochemical features including reactivity for keratins (AE1/AE3, CAM 5.2, CK18) in the papillary structures help distinguish this neoplasm from an ependymoma. The relative paucity of data compiled for this tumor makes giving an accurate diagnosis as well as a subsequent prognosis a daunting task. We discuss two cases of PTPR that were presented to us within a 3-mo span in order to elucidate the possible presentations of this extremely rare entity. Furthermore, we examine the 40 reported cases of PTPR in order to compare and contrast treatment modalities and to offer insight into the long-term prognosis of this unusual neoplasm. Upon completion of this presentation, participants should be able to describe the presentations of the rare entity, papillary tumor of the pineal gland, as well as the treatment modalities and prognosis of this unusual neoplasm. [35] Mechanism of brain edema following intracerebral hemorrhage. Jiping Qi, Harbin Medical University, Harbin, Heilongjiang, China. Intracerebral hemorrhage (ICH) can cause brain damage through inflammation-related pathways. In order to identify how the inflammatory mediators released from the blood after ICH cause edema formation, we tested the hypothesis Abstracts, 2009 Annual Meeting of the Association of Clinical Scientists 209 that thrombin activates the inflammatory cascade, which might play an important role in forming the brain edema after ICH. We produced ICH in adult Sprague Dawley rats by direct injection of autologous blood (50 µl) into the caudate nucleus. Patients with injured hippocampus were also enrolled in this study. Different expression levels of thrombin, protease activated receptor-1 (PAR-1), nuclear factor-kappa B (NFκB), macrophage inflammatory protein-2 (MIP-2), matrix metalloproteinase-9 (MMP-9), and aquaporin-4 (AQP-4) were detected in rat and human brain by immunohistochemistry, in situ hybridization, and quantitative real-time RT-PCR. Brain water content of the rats was also measured. We found that all of the inflammatory mediators showed dynamic changes according to the time of ICH. Their changing tendencies were in conformity with brain water content on the whole. Taken together, our findings indicate that: (a) thrombin activates an inflammatory cascade that may play an important role in the pathogenesis of brain edema after ICH; (b) NF-κB signaling is a key requirement for thrombin-induced inflammatory activation cascade after ICH; and (c) ICH-activated thrombin at PAR receptors may activate NF-κB, which, in turn, activates MIP-2 and MMP-9 to disrupt the blood–brain barrier, and then AQP-4 to induce brain edema formation. Upon completion of this presentation, participants should be able to diagram the proposed pathway for the pathogenesis of brain edema after cerebral hemorrhage. [36] Collagenous colitis in the pediatric population. Nina Tatevian, Sagar A. Dhamne, and William Klish, University of Texas–Houston Medical School and Baylor College of Medicine, Houston, TX. Collagenous colitis is a disease of unknown etiology predominantly seen in adults, with few cases reported in the pediatric age group. Clinical presentation in children is similar to that in adults, ie, chronic watery diarrhea with or without abdominal pain. The colonic mucosa is grossly normal by endoscopy. Histology reveals a collagenous band of varying thickness in the subepithelial region with occasional intraepithelial lymphocytes. No specific treatment other than symptomatic therapy is recommended. Here we report 9 children who presented in the years 2000-2008 with chronic watery diarrhea. Endoscopy showed a grossly normal colon. Colonic biopsies stained with H&E revealed a subepithelial collagen band in all the cases. This was confirmed using Masson’s trichrome stain. A systematic morphometric study to measure the maximum and minimum thickness of the subepithelial collagen band including the basal membrane was carried out on trichrome-stained sections using 40X magnification. The thickness of the band averaged 6.02 to 9.53 µm, with a range in individual cases from 4.7 to 12.73 µm. Minimal lymphocytic infiltrate was present in the glandular and surface epithelium. No acute inflammation or increased eosinophils were seen. In normal children, the collagenous plate is practically absent with a very thin basement membrane. The mere presence of a thickened collagen band is abnormal. In the presence of the clinical symptoms noted above, we conclude that these children have the pediatric counterpart of adult collagenous colitis. Upon completion of this presentation, participants should be able to diagnose collagenous colitis in pediatric subjects. [37] Pulmonary-renal syndrome: IgA nephropathy presenting with renal failure and pulmonary hemorrhage. Ewa Elenberg, Baylor College of Medicine, Houston, Texas. IgA nephropathy (IgAN) is the most common glomerular disease worldwide, usually renal limited. The pulmonary– renal syndrome (PRS) is defined as the combination of a diffuse alveolar hemorrhage and rapidly progressive glomerulonephritis. PRA is characterized by a fulminant course, thus early diagnosis is essential for correct therapy. The differential diagnosis commonly includes ANCA- associated vasculitides, Goodpasture syndrome, and systemic lupus erythematodes. IgAN presenting with renal failure and pulmonary hemorrhage is an extremely rare cause of PRS. There are only few cases reported worldwide. Mortality rate is high. The youngest previously reported patient was 17-yrold. We report a 14-yr-old male presenting with end stage renal disease (ESRD) due to IgAN and recent onset of dyspnea and hemoptysis. He gave a history of progressive orthopnea over a few days, with blood tinged sputum, gross hematuria, and anemia. Chest x-ray revealed an enlarged heart and pulmonary edema. CT scan of the lung revealed multiple illdefined nodular opacities and pulmonary capillaritis with interstitial thickening. The lung biopsy (Bx) revealed features suggestive of acute hemorrhage, fibrin, patchy organizing pneumonia, multifocal increased mucus, goblet cell hyperplasia, and mild anthracosis. The kidney Bx revealed IgAN with diffuse global sclerosis. Therapy (Rx) consisted of monthly iv cytoxan for 6 mo and pulses of solumedrol (1 g, iv, initially daily, then weekly). After 6 mo of Rx, cytoxan was replaced by methotrexate for 1 yr and the iv solumedrol was slowly weaned to every mo. With Rx, the patient did not have additional hemophtysis or pulmonary hemorrhage. The patient remains on chronic HD. This is the first report of an adolescent patient with IgA nephropathy presenting as ESRD and PRS. Upon completion of this presentation, participants should be able to itemize the differential diagnosis of pulmonary-renal syndrome and delineate the therapy for pulmonary-renal syndrome with IgA nephropathy. [38] Death of the autopsy and its underestimated utility in modern medicine. Gwendolin J. Godfrey and Joseph C. Parker, Jr., University of Louisville School of Medicine, Louisville, KY. The rate of post-mortem examination of hospital decedents has substantially declined in recent years. Reasons for this decline have involved every facet of medicine, from the decedents’ family, clinical medicine teams, hospital attorneys, and even the pathologists themselves. This overview illustrates how a complete post-mortem examination is conducted in a teaching institution through an interesting case study of an actual hospital autopsy. In addition, current research on the reasons for the declining autopsy rate and the benefits from performing autopsies will be reviewed. 210 Annals of Clinical & Laboratory Science, vol. 39, no. 2, 2009 Upon completion of this presentation, participants should be able to identify the common excuses for not requesting an autopsy and provide specific examples of how post-mortem examinations significantly contribute to understanding diseases and establishing the cause, manner, and mechanism of death. [39] Virtual cadavers for 21st century medical education and research. Donald Hilbelink, University of South Florida College of Medicine, Tampa, FL. Virtual cadaver development had its start with initiation of the Visible Human Project (VHP) by the National Library of Medicine in the early 1990’s. Visualization toolkits and software developed in conjunction with this project provide a means to produce accurate, high resolution virtual models of human anatomy. Although first limited to a small number of cadaver specimens provided by the VHP, advances in medical imaging and computer technology now permit high resolution imaging and modeling of any cadaveric specimen. During the past year all cadavers used for medical education by the USF College of Medicine were CT-scanned prior to use in the dissection laboratories. State-of-the-art software has been obtained and tested for use in 3D visualization and virtual dissection activities. Virtual cadaver images provide not only the opportunity for immediate cross-sectional anatomic correlation during the dissection, but also provide for a digital data base of virtual models of a wide range of anatomical variations and pathologies. The natural progression is to extend this technology to living patient medical image data to broaden the quality and quantity of virtual anatomical models for use in medical education and research. With this purpose in mind, the Human Morphoinformatics Research Center was established in 2008 in the College of Medicine at USF. Upon completion of this presentation, participants should be able to describe the nature of a virtual cadaver, how virtual cadavers are produced, and how virtual cadavers can be used in medical education and research. [40] Standardization of bioinformatics. Philip R. Foulis, James A. Haley Veterans Hospital and University of South Florida College of Medicine, Tampa, FL. Diagnostic medicine increasingly utilizes recent advances in genomics to diagnosis, classify, monitor, and treat patients. Clinical information systems need to manage these results and support the exchange of data based on genomics-related findings. Most current medical vocabularies lack rich terms to describe findings generated by molecular diagnostic and cytogenetic techniques. SNOMED-CT (College of American Pathologists) is ontology but lacks both significant granularity for detailed description of chromosomal structures and terms for the accurate description of molecular findings. Ontology comprises the concepts and relationships that describe molecular medicine. The Online Mendelian Inheritance in Man (National Library of Medicine and Johns Hopkins University) is clinically oriented. It is not provided in a machine-readable format suitable for integration with relational databases and applies inconsistent methods of describing genetic positional information. The Clinical Bioinformatics Ontology (CBO) is a construct that assists in codifying molecular medicine. The CBO addresses the gaps in current codification schemas by covering the areas of molecular genetics, molecular pathology, cytogenetics, and infectious disease, utilizing a semantically structured vocabulary for clinical molecular diagnostics. The attributes of the vocabulary provide standardized naming conventions and coded values describing clinically relevant molecular biological entities. The CBO contains a vocabulary, which is controlled by an oversight organization, and has uniquely identified concepts. This paradigm results in a codified representation of molecular medicine with a standardized terminology allowing extensive clinical and research possibilities as an added benefit because of its controlled scope. The standardization of laboratory test names, enhanced result interpretation, and completeness of reporting will assist with the delivery of healthcare. The capabilities of the CBO will be most beneficial in the areas of microbiology, anatomic pathology, and molecular pathology. Upon completion of this presentation, participants should be able to discuss the pros and cons of current codification methodologies with emphasis on molecular medicine, explain how a detailed molecular codification schema assists in the delivery of healthcare, and list the requirements for comprehensive bioinformatics ontology. [41] Recent algorithmic developments in content-based image retrieval systems in support of realizing clinicallydeployed solutions for surgical pathology. Jerome Y. Cheng and Ulysses J. Balis, University of Michigan Health System, Ann Arbor, Michigan. The investigation of content-based image retrieval (CBIR) has largely been an academic topic of interest for computer scientists and those active in automated evaluation of remote-sensing-based earth imagery. CBIR’s utility in the health sciences has been limited owing to two general factors: computational expense and limited use-cases where comprehensive digital imagery workflow is available for query. With the increasing availability of digital content for pathology, the challenge has essentially been confined to the need for improved computational methods. In this report, we present a novel set of algorithmic approaches targeted at solving the computational limitation for real-time CBIR applications in surgical pathology, based in particular on translationally and rotationally invariant vector ring kernel forms. This approach differs fundamentally from prior efforts in vector-based image classification in that the total possible degrees of freedom with the rotationally-invariant ring model are literally several million-fold less than prior constructs (with this decrement similarly representing an opportunity for commensurate improvements in computational performance). Representative digital histopathologic imagery data sets were selected for qualitative presence of one or more archetypal features (malignancy, unique cell type, structural configuration) and then analyzed with a discovery tool specifically designed to test the utility of individually-selected prototypic vectors. Results of vector matching performance analysis confirmed the utility of the spatially invariant hypothesis, with as few as even single vectors constituting a complete search kernel for both structural and cellular components within selected Abstracts, 2009 Annual Meeting of the Association of Clinical Scientists imagery. In many cases, computational times for feature matching were <1 min for representative fields of view, with extrapolation of this metric indicating that it is computationally possible to extend such approaches to image-library-wide pattern matching, in a real-time support model. These preliminary results demonstrate a possible algorithmic approach that will ultimately allow image-based query in surgical pathology as a routine imaging informatics tool. Upon completion of this presentation, participants should be able to discuss the prospect of using the computer for image-based queries in surgical pathology. [42] Method for analysis of signaling pathways in multiple organ failure. Mary F. McGuire, M. Sriram Iyengar, and David W. Mercer. University of Texas Health Science Center at Houston, Houston, TX. Multiple organ failure (MOF) is the leading cause of inhospital mortality following trauma. Pro- and anti-inflammatory cytokines have been implicated in MOF and their signaling pathways can potentially yield important information on the cellular mechanisms leading to MOF. We present a method for analysis of these signaling pathways over time and across clinical outcomes (MOF or Non-MOF). Eleven serum cytokines from 48 patients sustaining major torso trauma (excluding severe head injuries) who met standardized criteria were assayed and grouped in time periods (t = 2-6 hr, 6-10 hr, 10-14 hr, 14-18 hr, 18-22 hr, and 22-24 hr) by outcome. A significance set, S(t), the statistically significant cytokines differentiating outcomes, was derived using the one-sided Wilcoxon rank sum test with p <0.05. Ingenuity pathway analysis (IPA) generated molecular pathways for each time period t and for each outcome based on S(t). A time dependency matrix (TDM) was then generated with rows representing signaling molecules and columns showing time periods. Each cell contains a 1 or 0 depending on presence/absence of the signaling molecule in that time period. TDM enables mathematical analysis for questions of biological interest. This study identified 132 potentially significant signaling molecules. The analysis showed 67 in both outcomes in the same time periods; 31 in both outcomes at different times; 33 molecules appeared only in MOF or in NMOF at a single time, and one molecule implicated in apoptotic cell death appeared solely in two MOF time periods. In conclusion, our technique can provide detailed insights into molecular mechanisms evoked by trauma, with identification of potential drug targets and optimal time frames for therapy. Upon completion of this presentation, participants should be able to appraise the application of computer programs for ingenuity pathway analysis (IPA) and timedependency matrix (TDM) to generate mathematical solutions to questions of clinical interest, such as the signaling pathways in multiple organ failure. [43] Computer monitoring of quality in anatomic pathology. Myra L. Wilkerson, Geisinger Medical Laboratories, WilkesBarre, PA. We needed a software package to monitor quality in anatomic pathology that would encompass the entire work 211 unit, starting with clinician ordering and ending with final coding and billing. Data flow and specimen workflow were evaluated and a list of quality indicators was generated for each step. We then designed a database using Sybase, allowing us to retreive information from our anatomic pathology lab information system (CoPath v2.7, Cerner Corp.) into this new database without translationn. Other database tables were designed in MS SQL so that our software would have auditing capability. Web application windows were designed in Flex 2.0 (Adobe). Data were collected over the first 9 mo after deployment of the software with 3050 process errors recorded. Analysis shows that 70.4% of these errors occurred in the prelaboratory/preanalytic phase and included problems with incomplete information on requisitions, incorrect specimen labeling, and improper specimen packaging. The other top 2 categories where process errors occurred were histology (15.1%) and the grossing bench (13.3%). The data suggest that most delays in specimen processing result from prelaboratory errors and that we should focus on this area for quality improvement. Upon completion of this presentation, participants should be able to delineate the software requirements for monitoring and implementing a quality control program in anatomic pathology. [44] Personalized medicine will be the future. Pai C. Kao, Mayo Clinic, Rochester, MN. The human genome project, accomplished in 2001, revealed that many adverse drug reactions are caused by gene polymorphisms of drug metabolizing enzymes in patients. Phamacogenomics has been applied as personalized medicine. For many years, dentists wondered why codeine did not stop pain in some patients. In current knowledge, codeine has no pain-killing effect itself and requires hydroxylation to remove a methyl group at the 3-position, converting codeine to morphine by a cyp2D6 enzyme. Polymorphism of the gene causes some patients to lack the hydroxylating enzyme. A classic case of phamacogenomics/personalized medicine is codeine intoxication: a 62-year-old man hospitalized for pneumonia received the standard dose of 25 mg codeine tid for cough suppression. After 4 days, he fell into a coma. His blood morphine levels were 20 times the expected level. Genetic tests showed that he had more than 2 copies of the gene for the cyp2D6 enzyme. Fortunately, the patient was revived by iv infusion of naloxone. Pre-testing the patient’s genotype is the best way to prevent such severe adverse drug reactions. The reactions of a drug in patients can be divided into 3 groups: (a) ultra-rapid metabolizer, about 1-7%, the drug is metabolized rapidly from the body and has little therapeutic effect; (b) extensive metabolizer, about 80%, the drug is metabolized at a normal rate and has optimal therapeutic effect; (c ) poor metabolizer, about 5-10%, adverse drug reactions mostly occur in this group. It is estimated that each year, 2 million hospitalized patients have adverse drug reactions resulting in 100,000 deaths. Personalized medicine can minimize drug adverse reactions; the economic saving might cover the uninsured patients in the USA. The FDA is considering including genetic information on drug labels; 212 Annals of Clinical & Laboratory Science, vol. 39, no. 2, 2009 drug companies are also targeting the market for personalized medicine. Upon completion of this presentation, participants should be able to discuss various applications of pharmacogenomics to minimize drug adverse reactions. [45] Plasma BNP as a biochemical marker for patent ductus arteriosus in pre-term neonates. Vaneet K. Kalra, F. M. Kiblawi, A. Zauk and Vincent A. DeBari, Children’s Hospital at St. Joseph’s Regional Medical Center, Paterson, NJ, and School of Health and Medical Science, Seton Hall University, South Orange, NJ. Among pre-term neonates (PTN), patent ductus arteriosus (PDA) is highly prevalent and has been recognized as a significant cause of neonatal co-morbidity. The purpose of this study was to determine if levels of brain (or beta-type) natriuretic peptide (BNP), a peptide secreted by ventricular myocytes in response to volume or pressure overload, correlate with the size of the PDA. In a prospective design, 48 PTN (no PDA: n = 20; PDA: n = 28) were studied after obtaining parental consent. Those with genetic anomalies and congenital heart disease except for PDA and patent foramen ovale were excluded. Echocardiographic estimates of the diameters of the PDA (or absence of PDA) were made concurrently (within 4 hr) of capillary blood collection for BNP assay. BNP levels in samples from PTN without PDA were 27.4±8.6 pg/ml, with small PDA (n = 10), 62.3±34.4pg/ml, with moderate PDA (n = 11), 542.1±297 pg/ml, and with large PDA (n = 7), 2141.6±1699.7 pg/ml (p < 0.0001 for ANOVA; groupwise: p <0.05 for both no PDA vs moderate and large PDA and small PDA vs large PDA); trend analysis suggested a strong association of BNP with size of PDA (p <0.001). No correlation was found between BNP and either gestational age or birth weight. Logistic regression analysis of clinically relevant distinctions among size of PDA yielded a strong association (p <0.0001) with a cut-off of 119 pg/ml for the treat/no treat options. Assay of BNP may obviate the need for repeated echocardiography after treatment or to monitor the course of respiratory distress in PTN. Upon completion of this presentation, participants should be able to interpret BNP levels in patients with patent ductus arteriosus. [46] Association of D-dimer levels with clinical outcomes in patients presenting with acute pulmonary embolism. Maria Alfakir, J. Blamoun, A. I. Sedfawy, M. Q. Moammar, M. Maroules, M. A. Khan, and Vincent A. DeBari, St. Joseph’s Regional Medical Center, Paterson, NJ, and School of Health and Medical Science, Seton Hall University, South Orange, NJ. The D-dimer fragment of fibrin degradation has been a useful adjunct in the diagnosis of venous thromboembolism (VTE). In conjunction with predictive algorithms, the high negative predictive value (NPV) of D-dimer measurements has provided this analyte with a prominent position in the diagnosis of pulmonary embolism (PE). The purpose of this study was to determine if D-dimer levels correlate with ventilation/perfusion (V/Q) derangements as assessed by the alveolar-arterial oxygen tension gradient (ΔA-a) and to ascertain if quantitative measurements of D-dimer on admission have prognostic value in terms of during-admission mortality and recurrence over a 60-wk period. The study utilized a retrospective cohort of 108 subjects admitted to a single institution and studied longitudinally. The cohort was divided into 4 groups representing degree of severity assessed by CT-angiography: mild, moderate, severe, and very severe. Differences among D-dimer levels among these groups were significant (p <0.0001). Strong correlation was observed between D-dimer concentration and ΔA-a (p <0.0001). Logistic methods were used to calculate a “cut-off” level that would distinguish mild-moderate from severe-very severe PE. At a concentration of 12.35 μg/ml, this level yielded an odds ratio (OR) = 12.64 (p = 0.006) for during-admission mortality and a hazard ratio (HR) = 0.13 (p <0.0001) for 60-wk recurrence. These data suggest that D-dimer levels have utility beyond their NPV and should be considered as potential prognostic markers in subjects presenting with acute PE. Upon completion of this presentation, participants should be able to interpret the prognostic significance of Ddimer levels in patients with acute pulmonary embolism. [47] Poloxamer 188 prolongs survival of hypotensive resuscitation and decreases vital tissue injury after full resuscitation. Robert L. Hunter, Jr., Rongzhen Zhang, Ernest A Gonzalez, and Frederick A Moore, University of Texas-Houston Medical School and The Methodist Hospital, Houston, TX. Hypotensive resuscitation prolongs survival of patients with severe bleeding until they can undergo hemorrhage control. However, its value is limited by continuing ischemic injury. Purified poloxamer 188 (P188), a copolymer with rheologic and cytoprotective activities, was known to reduce mortality of hemorrhagic shock when used as an adjunct to full resuscitation with fresh whole blood and crystalloid. Studies were undertaken to determine if it could prolong survival and reduce reperfusion injury during prolonged hypotensive resuscitation when added to the best regimen currently available. Unanesthetized rats were bled to a mean arterial pressure (MAP) of 30 mmHg for 30 min under computer control. They then received hypotensive resuscitation with Hextend or Hextend + P188 to maintain a MAP of 60 mmHg until death. P188 improved auto-resuscitation, reduced fluid requirements, and increased the survivable duration of hypotensive resuscitation by over 3 hr (p <0.01). Additional studies assessed tissue damage after shock and hypotensive resuscitation with Hextend followed by full resuscitation with crystalloid. In these studies, P188 blunted the no reflow phenomenon and largely prevented myocardial injury, pulmonary inflammation, small bowel damage, renal tubular necrosis, hepatic central lobular necrosis, and apoptosis of splenic germinal centers that occurred during full resuscitation. Additional studies demonstrated that P188 increased survival from 0% to 75% in 50% volume controlled hemorrhage (p <0.001). Finally, P188 did not increase bleeding in uncontrolled hemorrhage produced by 75% tail amputation. Since, P188 prolongs survival, decreases fluid requirements, and reduces tissue damage, it deserves further Abstracts, 2009 Annual Meeting of the Association of Clinical Scientists consideration as an adjunct to hypotensive resuscitation. Supported by US Army Grant W81XWH-06-1-0570. Upon completion of this presentation, participants should be able to comment on the potential utility of Poloxamer 188 as a therapeutic adjunct during resuscitation. [48] Unique properties of aluminum maltolate in experimental studies of neurodegeneration. John Savory, University of Virginia Medical School, Charlottesville, VA. It is over 40 years since Klatzo et al reported that the intracisternal administration of aluminum (Al) phosphate to New Zealand white rabbits produced intraneuronal protein aggregates which on silver staining appeared remarkably similar to the neurofibrillary tangles of Alzheimer’s disease. Most subsequent studies of Al-induced neurodegeration have followed Klatzo’s work and used inorganic Al compounds that are highly insoluble at physiological pH, making it difficult to reproduce dose (Al3+)-response data. The choice of an appropriate Al compound is important for obtaining consistent results since at neutral pH many of these compounds form insoluble precipitates. The chemistry of Al is complex and should be understood in assessing investigations employing Al as a toxic agent. Most studies carried out in the author’s laboratory have employed Al maltolate, which is soluble at neutral pH and can be delivered to brain tissue via the intracisternal route of administration without the complications of Al(OH)3 precipitation. The primary constituent of paired helical filaments in human neurofibrillary tangles is tau, although other proteins are present. Studies in the author’s laboratory have provided insight into the mechanisms of apoptosis involved in the neurodegenerative process including mitochondrial and endoplasmic reticulum stress involving caspase-12 and caspase-3 activation. Overall, the Al/rabbit model system has provided useful information on several processes that could share a common mechanism with the development of neurodegeneration in Alzheimer’s disease and this model should continue to be valuable as more mechanistic schemes are uncovered. The model could be of value in identifying early diagnostic markers and preventative or therapeutic strategies for Alzheimer’s disease. Upon completion of this presentation, participants should be able to compare the neurodegeneration induced in rabbits by intracisternal infusion of aluminum maltolate with that seen in patients with Alzheimer’s disease. [49] Anti-tumor effect of ent-11a-hydroxy-15-oxo-kaur-16en-19-oic-acid in mouse models of liver and lung tumors. George G. Chen,1 Jackie Leung,1 Nian Ci Liang,2 Michael K.Y. Hsin,1 Kefen Wu, 2 Yi Feng Deng,2 Johnson H.Y. Yip,1 Xianling Gong,2 Yingnian Lu,2 Naomi M.W. Choi,1 Malcolm J. Underwood,1 and Paul B.S. Lai.1 1The Chinese University of Hong Kong, Shatin, Hong Kong; 2Guangdong Medical College, Zhanjiang, Guangdong, China Ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid (5F) is a chemical compound extracted from Pteris semipinnata L. Apoptotic effect induced by 5F has been documented in several in vitro tumor cell lines but not yet been tested in vivo. In this study, the therapeutic effects of 5F were investigated in mouse models of hepatocellular carcinoma (HCC) and lung 213 cancer. Diethylnitrosamine was used to induce HCC in C3H/HeJ mice. 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)1-butanone was administrated to induce lung tumor in A/J mice. Tumor-bearing mice were given 5F with 12, 24, 48 mg/ kg of 5F daily ip, and control mice were given vehicle. It was found that mice receiving 48 mg/kg of 5F alone, and those receiving 12, 24 mg/kg plus 5-fluorouracil (5-FU) had a significant decrease in target organ weights, surface tumor number, and total tumor volume in both groups. Cell proliferation index revealed that all liver tissues from mice receiving 5F treatment were less proliferative than the nontreatment group. Mice with 48 mg/kg treatment had highest value of TUNEL among all groups. Pro-apoptotic proteins Bax and Bak were strongly expressed in the 48 mg/kg alone group, and 12, 24 mg/kg plus 5-FU group. Nuclear factor kappaB (NF-kB) was highly suppressed in the above stated groups. Suppression of Bcl-2 was observed in all 5F treatment groups. 5F treatment increased Bax and Bak expression but decreased Bcl-2 and NF-kB levels compared with the tumorbearing non-treatment group. Collectively, 5F alone has a therapeutic effect on both liver and lung tumors, especially at the higher doses and 5-FU in combination with the lower doses (12-24 mg/kg) of 5F may have an additive effect on the inhibition of tumor. Therefore, 5F is a promising novel antitumor agent. (This study was supported by ITF of Innovation and Technology Commission, the Government of the Hong Kong Special Administration Region, GHP/022/06.) Upon completion of this presentation, participants should be able to discuss how the herbal-extracted compound ent-11a-hydroxy-15-oxo-kaur-16-en-19-oic-acid inhibits the growth of liver and lung tumors in mouse models. [50] Mercury in the environment. Ernest M. Walker, Jr., Sandra M. Walker, Kevin Rice, and Eric R. Blough, Marshall University School of Medicine and Marshall Community and Technical College, Huntington, WV. Mercury, a highly toxic and hazardous environmental contaminant, exists naturally and as a human-introduced contaminant, progressively increasing the amount of atmospheric mercury, which may enter atmospheric-soilwater distribution cycles and be circulated for years. Mercury poisoning (hydrargaria or mercurialism) results from exposure to mercury or its compounds and the toxic effects depend on its chemical form and route of exposure. Ingested elemental mercury is usually absorbed relatively slowly and may pass through the digestive system without causing damage. Ingested inorganic compounds may damage the gastrointestinal tract and cause kidney failure. Organic mercurials, such as methylmercury, can irreversibly damage the immune, genetic, metabolic, and nervous systems, particularly in developing embryos, who are five to ten times more sensitive than adults. Certain bacteria in the environment take up inorganic mercury and convert it to methylmercury. These bacteria may be consumed by the next higher level in the food chain, or release methylmercury into water, where it can adsorb to plankton and work up the food chain. People are exposed to methylmercury largely by eating contaminated fish, seafood, and wildlife that are at the top of food chains. Ingested mercury may undergo bioaccumulation leading to 214 Annals of Clinical & Laboratory Science, vol. 39, no. 2, 2009 progressive increases in body burdens. Many toxic effects of mercury are partially or wholly reversible through specific therapy, decreased exposure, and natural elimination of the metal after exposure has been discontinued. Treatment of mercury poisoning is difficult. Only DMSA (2,3-dimercaptosuccinic acid) is FDA-approved to treat inorganic mercury in children. Other agents sometimes used include DMPS (2,3dimercapto-1-propanesulfonic acid), DPCN (D-penicillamine), or BAL (dimercaprol). No FDA-approved chelator exists for methylmercury or ethylmercury treatment although oral DMSA is the most frequently used. Upon completion of this presentation, participants should be able to explain the health hazards and toxic mechanisms, especially to developing fetuses, following exposures to mercurial compounds, especially methylmercury, [51] Deferasirox and iron removal in the iron overloaded gerbil model. Rabaa M. Al-Rousan, Ernest M. Walker, Joseph P. Laurino, Satyanarayana Paturi, and Eric R. Blough, Marshall University School of Medicine, Huntington, WV, and University of Tampa, Tampa, FL. Transfusional iron overload in thalassaemia and other conditions is the most common metal-related toxicity disorder with the highest mortality rate worldwide. Iron overload leads to iron deposition in the heart, liver, and endocrine tissues resulting in serious disease states including cardiomyopathy, hepatic fibrosis, and diabetes mellitus. Deferasirox is a novel tridentate oral iron chelator that was recently approved for the treatment of transfusional iron overload. The objective of this study is to evaluate the ability of deferasirox to remove stored tissue iron and prevent or reverse iron-induced tissue injury. Adult male Mongolian gerbils were randomly divided into 3 groups: control, iron overload, and iron overload + deferasirox treatment (n = 8/group). Iron-dextran was given 100 mg/kg/ 5d ip for 10 wk. Deferasirox treatment was undertaken postiron loading and was given at 100 mg/kg/d po. Iron levels in heart, liver, and pancreas were determined by inductively coupled plasma atomic emission spectrometry (ICP-AES) and Prussian blue iron staining was performed to examine iron deposition in the corresponding tissues. Hydroethidine fluorescence, oxyblot, and immunoblotting analyses were used to evaluate indices of cardiac and hepatic oxidative stress. Compared to the untreated group, the data show that deferasirox treatment for three mo resulted in 23.5%, 43.5%, and 38% reductions in cardiac, hepatic, and pancreatic iron levels, respectively (p <0.05). Histological examination revealed reduced iron deposition and superoxide production with deferasirox treatment. Deferasirox-mediated reductions in tissue iron levels were associated with decreases in tissue ferritin and diminished indices of oxidative stress. Taken together, these results demonstrate that deferasirox removes excess tissue iron and has a protective effect against ironinduced cellular insult. Upon completion of this presentation, participants should be able to weigh the strength of the experimental evidence and speculate about the potential clinical use of deferasirox for therapy of iron-overload in patients. [52] Overview of iron metabolism and hemochromatosis. Donald J. Cannon, The University of Tampa, Tampa, FL. Iron is critical to our industries and indispensable to many functions in the human body, including its role in the transport of oxygen as a constituent of hemoglobin. We continually ingest iron in our diet and lose some every day. Maintaining a balance in this element depends on the processes of iron absorption, transport. storage, erythrocyte turnover, and the individual’s genetic makeup. Pathological conditions arise from both deficiencies and excesses of iron. Among the latter is hemochromatosis, a disease that can either be acquired or caused by an autosomal genetic disorder. Primary hemochromatosis is hereditary with a genetic defect in the HFE gene or other genes that regulate absorption, transport, and storage of iron. Hemochromatosis can become manifest at any age, but it is seen chiefly between the ages of 30 and 50 yr in men and after the age of 50 yr in women. Hemochromatosis is treatable, under-diagnosed, and may contribute to the development of cancer and diabetes. Various clinical laboratory tests of iron metabolism will be reviewed, as well as tthe genetic tests for hemochromatosis. Continual education of the public and health care professionals about hemochromatosis is needed to increase awareness of this relatively common and sometimes fatal disease. Upon completion of this presentation, participants should be able to describe the silent and occult nature of iron buildup in hemochromatosis and discuss steps to ameliorate this condition. [53] HLA sequence-based typing. Kaaron Benson, H. Lee Moffitt Cancer Center, Tampa, FL. HLA typing has evolved from use of serologic to molecular methods. Of the molecular methods commonly employed, sequence-based typing (SBT) allows for high resolution typing and allele-level results. Stem cell transplantation programs have expanded the number of HLA loci typed from three (HLA-A, B, DRB1) to five (HLA-A, B, Cw, DRB1, DQB1) to allow for improved engraftment and reduced graft-vs-host disease rates, particularly when unrelated donors are necessary. When HLA-matched, related donors are not available, HLA-matched, unrelated donors offer potential cures to patients with previously incurable diseases. Upon completion of this presentation, participants should be able to list 2-3 advantages of molecular HLA typing over use of serologic methods, outline the basic steps in molecular HLA assays, and select the best donor from a roster of HLA-mismatched, unrelated donors. [54] Hereditary thrombophilia and the molecular pathogenesis of Factor V Leiden. M. Kent Froberg, Saint Mary’s Duluth Clinic, Duluth, MN Hereditary thrombophilia affects 5-8% of the USA population, causing deep venous thrombosis (DVT) and pulmonary emboli leading to 60,000 deaths annually. Congenital causes of thrombogenic disease include deficiencies in Proteins C, S, and anti-thrombin III; and mutations in enzymes of homocysteine metabolism, prothrombin, and Factor V. Normally Factor V is a cofactor for activation of Abstracts, 2009 Annual Meeting of the Association of Clinical Scientists Factor X which leads to conversion of thrombin from prothrombin and the ultimate production of fibrin from fibrinogen, Activated Factor V is inactivated by activated Protein C as a major step in anticoagulation. Factor V Leiden mutation leads to activated protein C resistance and accounts for more than 50% of hereditary thrombophilia. The most common genetic change in Factor V Leiden involves an arginine to glutamine substitution at amino acid position 506 making Factor V resistant to proteolysis by activated protein C. This arginine residue is the preferred catalytic site for activated Protein C degradation of Factor V. This mutation prevents inactivation of Factor V, but does not prevent its activation, hence the accumulation of activated Factor V leads to a procoagulant state and increased risk of DVT. Factor V Leiden is likely when activated Protein C resistance is present. Factor Va levels remain increased and the clotting time is shortened. Molecular diagnosis of Factor V Leiden mutation may be confirmed by PCR assay using a restriction enzyme that specifically cleaves Factor V at the 506 position and facilitates automated diagnosis from small blood samples. Upon completion of this presentation, participants should be able to name the most common causes of hereditary thrombophilia, explain the role of Factor V in normal clotting, discuss the role of activated Protein C in anticoagulation, and tell how Factor V Leiden mutation leads to activated Protein C resistance and an increased risk of deep vein thrombosis. [55] Feto-maternal hemorrhage detection techniques. Jonathan S. Krauss, The Medical College of Georgia, Augusta, GA The incidence of hemolytic disease of the newborn (HDN) has been dramatically reduced due to tests that both identify and quantify, to dose Rh(0)(D) immune globulin, feto-maternal hemorrhage (FMH) in Rh-negative (-) mothers. Tests for fetal red blood cells (RBCs) in the maternal circulation recognize either (a) hemoglobin F (Hb F) containing RBCs, or (b) Rh-positive (+) RBCs. The identification of HbF cells in the maternal circulation for FMH quantification is restricted by maternal hereditary persistence of fetal hemoglobin (HPFH) and other hemoglobinopathies, which can elevate the maternal Hb F level. The categorization of Rh+ RBCs in the maternal circulation for FMH is limited by the need for fetal Rh phenotype determination, which can be elucidated by molecular methods, thus lessening the utility of this strategy, antenatally, however. Acid elution of Hb A (Betke-Kleihauer; B-K) is the most traditional technique, however, its accuracy and precision are suboptimal, and interpretation of the B-K blood smear requires expertise. An automated cytometric/ morphometric method has improved the coefficient of variation (CV) of the B-K test. Immunologic Hb F identification methods are primarily flow cytometric; accuracy and precision may be improved by dual-staining for carbonic anhydrase (CA), which is absent antenatally; fetal cells are Hb F+/CA-; adult cells are Hb F-/CA+. Dual color flow cytometry of Hb F and Rh(0)(D) recognizes Rh+ fetal RBCs. Flow cytometry can also be used to pinpoint Rh(0)(D) alone; also, an automated hematology analyzer has been adapted to quantify anti-Rh(0)(D) labeled cells. Rh+ cells can be 215 identified by rosette and agglutination methods, which require less instrumentation than flow cytometry. Techniques for quantification of FMH have gradually improved, primarily due to advances in flow cytometry. Upon completion of this presentation, participants should be able to describe the limitations and advantages of the different methods for quantitation of fetomaternal hemorrhage in Rh-negative mothers. [56] Dermatopathologic manifestations of biowarfare agents. Michael B. Morgan, University of South Florida College of Medicine, Tampa, FL. Although the potential cutaneous manifestations of the various biowarfare/terrorist agents are manifold, key clinical and pathologic alterations can be expected in their setting. The most important and potentially deadly biowarfare agents include anthrax and smallpox. Anthrax is caused by the bacterium Bacillus anthracis, a Gram-positive spore-forming bacillus. Endogenous principally to cattle producing countries such as Scotland, the United States, and Argentina, among others, this organism is considered to be zoonotic among cows with man being occasionally infected following accidental inhalation of the infective spores or handling of contaminated furs/hides. The principal forms of the disease include inhalational disease, producing hemorrhagic pneumonia and associated with poor prognosis, gastrointestinal disease, and cutaneous disease. The cutaneous lesions consist initially of a hemorrhagic papule usually seen on or around the hands that evolves within days to a blackened ulcer referred to as an eschar. Associated regional lymphadenopathy is commonly observed. The pathogenesis involves the engulfment of the organisms within macrophages that may remain localized or proceed to the lymph nodes. B. anthracis produces 3 important pathogenic factors responsible for enhancing its virulence: a protective capsule, an edema factor, and a lethal factor. The diagnosis of anthrax follows isolation of the organism where a presumptive diagnosis can be rendered on the basis of the characteristic Gram-staining attributes, or confirmed with the characteristic medusa-head colonial morphology seen. Smallpox, otherwise referred to as variola, is a deadly microbe known throughout recorded history. The cause is a orthopox virus last seen naturally in the early 1970’s and since relegated to biowarfare laboratories in the former USSR and the CDC in Atlanta. The virus is obtained following respiratory inhalation of infective droplets and produces a localized infection of the airways followed by viremia and later, cutaneous disease. The cutaneous lesions occur as a single crop producing hemorrhagic macules followed by papules that ulcerate finally leaving depressed (varioloform) scars. Unlike chickenpox (varicella) with which it may be confused, the lesions are concentrated upon the extremities and face and show lesions that are temporally and isomorphically related. Pathology of the lesions shows a combination of reticular and balooning epithelial degeneration with characteristic intra-cytoplasmic viral inclusions referred to as Guarneri bodies. The case fatality rate of smallpox is high, with most complications stemming from pneumonia, encephalitis, and disseminated intravascular coagulation. 216 Annals of Clinical & Laboratory Science, vol. 39, no. 2, 2009 Diagnosis can be achieved by biopsy, serology, culture, or electron microscopy. Treatment with antivirals is available. Patients diagnosed with the disease should be immediately isolated and public health authorities notified. The implications of diagnosis of smallpox are ominous and should engender consideration of biowarfare or terrorist attack. Upon completion of this presentation, participants should be able to distinguish between the important biowarfare microbes that present with cutaneous manifestations and describe the pathogenesis of the histologic and clinical attributes of these organisms. [57] Influenza: Considerations in children and adolescents. Armand Glassman, Medical University of South Carolina, Charleston, SC. The purpose of this work is to examine the role of influenza in morbidity and mortality of children and adolescents (C&A). Data from the Centers for Disease Control & Prevention (CDC) for the 2006-2007 influenza season were reviewed to provide information regarding deaths in C&A. A total of 76 deaths for this group were reported in this time period. The predominant organism was influenza A/New Caledonia, a type H1N1 strain. This strain was included in the trivalent vaccine that year. It is estimated that vaccine efficacy ranges from 70 to 90 % assuming that there is a good match of the vaccine antigen(s) and the epidemic virus. Two types of vaccines are available. The more commonly used one is the trivalent inactivated vaccine (TIV), which must be injected. A live attenuated influenza vaccine (LAIV) administered by nasal spray is available. LAIV is more effective than TIV in young children. The Advisory Committee on Immunization Practices (ACIP) recommends influenza vaccination for all children 6 mo to 18 yr of age. Influenza variants that were not part of vaccines have been the cause of 80% of epidemics in the last few years. The present TIV contains one H1N1, one H3N2, and one influenza B viral antigen. Diagnosing outbreaks includes clinical presentation and a variety of on site rapid tests. Viral cultures are necessary to characterize the specific virus & antigens. Antiviral drug selection for the treatment of influenza presents challenges. Amantadine and rimantadine are ineffective for H3N2 strains. Oseltamivir, a neuraminidase inhibitor, is not effective against many H1N1 strains. Influenza is associated with significant disease and death in C&A. Universal vaccination of C&A has been recommended by the ACIP. Vaccination and therapy for influenza have limitations. Upon completion of this presentation, participants should be able to recount the current status of vaccines against influenza strains and the antiviral drugs that are available for treatment of influenza infection in children and adolescents. [58] Multi-drug resistant Acinetobacter infections in Iraq veterans: The Tampa VA experience. L. Brannon Thomas, A.A. Borkowski, M.J. Kasper, A.V. Heal, F.J. Kinney, J. N.Burgett, R.L. Oehler, S.G. Scott, B. Neugaard, and S.M. Mastorides, James A. Haley Veterans Hospital, Tampa, FL. Infections with multi-drug resistant Acinetobacter (MDR-Acb) are an increasing problem in hospitals worldwide, and these infections are extremely common among casualties of Operation Iraqi Freedom (OIF). We will review our current understanding of MDR-Acb infections in veterans of OIF, and explore problems and potential solutions to developing rapid detection (PCR based) screening tests for these infections. Emphasis will be on the findings from patients admitted to the James A. Haley Veterans Hospital in Tampa, FL. This facility is one of the nation’s largest veterans’ hospitals, and one of only four designated VA poly-trauma rehabilitation centers. We performed a retrospective chart review tracking OIF veterans admitted to our facility from injury through rehabilitation, finding that 56% had cultures positive for Acb. Of these, 85% were with MDR strains (defined as resistant to ≥4 classes of commonly tested antibiotics). In 25% of these veterans, at least one culture was resistant to all antibiotics tested. The most common mechanism of injury was from improvised explosive devices (IEDs), although patients with non-penetrating injuries were colonized and/or infected as well. Most positive cultures were from the skin, respiratory tract, or wounds, with many additional sites encountered. Veterans with MDR-Acb infections had lengthened hospital and rehabilitation stays (128.6 days compared to 89.2 days in patients without MDRAcb infections). Furthermore, these admissions coincided with a greater than 6-fold increase of multi-drug resistance in Acb infections in non-OIF patients admitted to our facility. MDR-Acb infections produce challenges in both treatment and containment, and, due to diverse mechanisms of drug resistance, difficulties with developing rapid screening tests. Upon completion of this presentation, participants should be able to define multi-drug resistant Acinetobacter infections, discuss the basic mechanisms involved in drug resistance, summarize current theories regarding the origin of these infections in casualties of Operation Iraqi Freedom, delineate the dissemination risk of these infections in the hospital setting, and describe the difficulty of developing rapid screening tests.
© Copyright 2024